Tagged with cannabis

Cannabis Founded in 1998, GW Pharmaceuticals is a true pioneer in cannabinoid medicines and the only pharmaceutical company with a license to cultivate cannabis in the UK. “While people were wary of cannabis, they became very aware that it was treating patients with severe conditions, where other medicines had either failed…

UK Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of his company. Unlike many of your peers, you are very optimistic about Brexit. What opportunities do you believe Brexit will…

Canada As cannabis in Canada cruises towards legalization, Pharma giants race for patented products.   Big Pharma is establishing a significant cannabis presence in Canada with registered patents in advance of legalization. As cannabis-plant-based drugs proliferate globally, opportunities for new technologies and revolutionary advances in health and wellness sciences will continue…

Canada Canada’s medical cannabis market is valued as a USD 1.3 billion market opportunity, with the recreational market potential worth over USD eight billion. Ontario is the Canadian state with by far the largest number of licensed cannabis producers with 57 compared to just 22 in second-placed British Colombia and seven…

Global The global regulatory landscape for medical cannabis, showing the countries in which medical cannabis and cannabinoid treatments are legal / essentially legal, illegal but often unenforced, decriminalized, and illegal.   Made with Visme Infographic Maker   Click here to download our report on Canada’s world-leading medical cannabis industry

Cannabis One area in which the island nation of Malta has been a first mover in embracing disruption has been its controversial entry into the global cannabinoid market. The medical cannabis market within the EU is expected to be worth USD 56 billion by 2020 with leading European nations such as…

Cannabis While many Canadian medical cannabis outfits cover the entire value chain, from research and development through to manufacturing and distribution, others – such as Canopy Health and Tetra Bio-Pharma – are taking their cues from the biotechnology industry and strictly focusing on clinical trials.   I believe that across the…

Malta Marius Calleja, general manager of Maltese contract manufacturer, Starpharma, discusses the company’s current growth strategy and how Starpharma can capitalize on the emergent medical cannabis niche.       Even though you only started as general manager six months ago, can you describe the evolution of Starpharma over the years?…

Canada “If you are trying to be everything to everybody, you end up being nothing to no one”—Michael Gorenstein, CEO of The Cronos Group talks to PharmaBoardroom about his unusual career path, the company’s dual focus on medicinal and recreational cannabis, and how Canada will always remain the core center of…

Malta Paul Apap Bologna, managing director at Associated Drug Company (ADC), introduces his family company, focused on distributing high-quality innovative solutions to Maltese patients, and evokes the key opportunities that the medicinal cannabis segment can represent for Malta and the industry. Established in 1930, Associated Drug Company (ADC) has a long…

Malta Prof. Claude A. Farrugia of the Malta Chamber of Commerce, Enterprise and Industry documents the main trends in the manufacturing industry of Malta and discusses the island’s strengths in discovering new niches and exploiting opportunities as they present themselves. Farrugia also touches on the development of a biotech industry on…

Canada With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO Neil Closner also highlights MedReleaf’s important efforts in conducting R&D and clinical studies in order to present practitioners with relevant…